NO3006443T3 - - Google Patents

Info

Publication number
NO3006443T3
NO3006443T3 NO14807340A NO14807340A NO3006443T3 NO 3006443 T3 NO3006443 T3 NO 3006443T3 NO 14807340 A NO14807340 A NO 14807340A NO 14807340 A NO14807340 A NO 14807340A NO 3006443 T3 NO3006443 T3 NO 3006443T3
Authority
NO
Norway
Application number
NO14807340A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3006443T3 publication Critical patent/NO3006443T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO14807340A 2013-06-06 2014-06-06 NO3006443T3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013119416 2013-06-06
PCT/JP2014/065141 WO2014196644A1 (ja) 2013-06-06 2014-06-06 ベンゾチオフェン化合物

Publications (1)

Publication Number Publication Date
NO3006443T3 true NO3006443T3 (no) 2018-09-22

Family

ID=52005968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14807340A NO3006443T3 (no) 2013-06-06 2014-06-06

Country Status (31)

Country Link
US (2) US8981119B2 (no)
EP (1) EP3006443B1 (no)
JP (1) JP6314978B2 (no)
KR (1) KR102253721B1 (no)
CN (1) CN105263926B (no)
AR (1) AR096544A1 (no)
AU (1) AU2014275768B2 (no)
BR (1) BR112015030533B1 (no)
CA (1) CA2914606C (no)
CY (1) CY1120341T1 (no)
DK (1) DK3006443T3 (no)
ES (1) ES2671818T3 (no)
HK (1) HK1215570A1 (no)
HR (1) HRP20180722T1 (no)
HU (1) HUE038920T2 (no)
IL (1) IL242800B (no)
LT (1) LT3006443T (no)
MX (1) MX2015016743A (no)
NO (1) NO3006443T3 (no)
PH (1) PH12015502637A1 (no)
PL (1) PL3006443T3 (no)
PT (1) PT3006443T (no)
RS (1) RS57250B1 (no)
RU (1) RU2667507C2 (no)
SG (1) SG11201509989VA (no)
SI (1) SI3006443T1 (no)
TR (1) TR201808724T4 (no)
TW (1) TWI624466B (no)
UA (1) UA117484C2 (no)
WO (1) WO2014196644A1 (no)
ZA (1) ZA201508866B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001056A2 (pt) * 2019-07-23 2022-05-24 Astellas Pharma Global Dev Inc Métodos de tratamento de distúrbios do sono associados a dor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614639A (en) * 1995-03-31 1997-03-25 Eli Lilly And Company Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof
EP1358150A1 (en) * 2001-02-06 2003-11-05 Glaxo Group Limited Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
US20060205751A1 (en) 2003-07-15 2006-09-14 Smithkline Beecham Corporation Novel compounds
WO2008054435A2 (en) * 2006-01-09 2008-05-08 The Regents Of The University Of California Use of sk channel activators to prevent relapse/reinstatement of drugs of abuse
US8022209B2 (en) * 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
KR20110096541A (ko) * 2008-11-10 2011-08-30 베링거 인겔하임 인터내셔날 게엠베하 중간-전도성 칼슘-활성화된 칼륨 채널을 통해 세포-세포 융합을 조절하기 위한 조성물 및 방법
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio

Also Published As

Publication number Publication date
WO2014196644A1 (ja) 2014-12-11
IL242800B (en) 2019-06-30
US20150133433A1 (en) 2015-05-14
KR102253721B1 (ko) 2021-05-18
JP6314978B2 (ja) 2018-04-25
SI3006443T1 (en) 2018-08-31
EP3006443A1 (en) 2016-04-13
RU2015152150A (ru) 2017-07-13
TR201808724T4 (tr) 2018-07-23
US8981119B2 (en) 2015-03-17
PH12015502637B1 (en) 2016-03-07
BR112015030533B1 (pt) 2023-02-28
MX2015016743A (es) 2016-03-21
AU2014275768A1 (en) 2015-12-17
UA117484C2 (uk) 2018-08-10
HRP20180722T1 (hr) 2018-06-15
BR112015030533A2 (pt) 2020-10-20
EP3006443A4 (en) 2016-12-21
IL242800A0 (en) 2016-02-01
HK1215570A1 (zh) 2016-09-02
ZA201508866B (en) 2017-11-29
KR20160015281A (ko) 2016-02-12
PH12015502637A1 (en) 2016-03-07
AR096544A1 (es) 2016-01-13
TW201536775A (zh) 2015-10-01
AU2014275768B2 (en) 2017-12-14
CY1120341T1 (el) 2019-07-10
JPWO2014196644A1 (ja) 2017-02-23
DK3006443T3 (en) 2018-06-25
LT3006443T (lt) 2018-07-10
HUE038920T2 (hu) 2018-12-28
SG11201509989VA (en) 2016-01-28
RU2667507C2 (ru) 2018-09-21
EP3006443B1 (en) 2018-04-25
CN105263926B (zh) 2018-05-11
CA2914606A1 (en) 2014-12-11
PL3006443T3 (pl) 2018-09-28
US9399038B2 (en) 2016-07-26
TWI624466B (zh) 2018-05-21
RS57250B1 (sr) 2018-07-31
US20140364421A1 (en) 2014-12-11
PT3006443T (pt) 2018-06-07
CA2914606C (en) 2021-03-23
ES2671818T3 (es) 2018-06-08
CN105263926A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
AP2016009275A0 (no)
BR112015007533A2 (no)
BR112016010923A2 (no)
BR112014018502A2 (no)
BR112014019326A2 (no)
BR112014018516A2 (no)
BR112014020341A2 (no)
BR112014018480A2 (no)
BR112014017669A2 (no)
BR112014021878A2 (no)
BR112014018468A2 (no)
BR112014018207A2 (no)
BR112014017901A2 (no)
BR112014019204A2 (no)
BR112015015948A2 (no)
BR112016002115A2 (no)
BR112014018578A2 (no)
BR112014018483A2 (no)
BR112016015033A2 (no)
BR112015015312A2 (no)
BR112014018353A2 (no)
BR112014018496A2 (no)
BR112014018514A2 (no)
BR112014024039A2 (no)
BR112014017992A2 (no)